Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma

NCT05143112 is registered in ClinicalTrials.gov with Shenzhen University General Hospital as lead sponsor.

NCT NCT05143112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05143112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma
Lead sponsor
Shenzhen University General Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
February 5, 2021
Completion date
February 29, 2024
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma,b cell